Adapting Biopharma to AI: A 2024 Update with Greg Meyers
Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb, or BMS, joins Jorge Conde, general partner at a16z.
This is a follow-up to their 2023 episode, where they discussed how biopharma can adapt to AI. Now, they revisit the conversation to see what’s changed and what hasn’t.
Together, they chat through tech as a competitive differentiator for large companies, generative AI for drug development, and what Greg and BMS look for in potential partners. They also highlight the importance of being agile and adaptable while navigating the changing landscape of biotech, providing valuable insights for founders.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
More description
Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb, or BMS, joins Jorge Conde, general partner at a16z.
This is a follow-up to their 2023 episode, where they discussed how biopharma can adapt to AI. Now, they revisit the conversation to see what’s changed and what hasn’t.
Together, they chat through tech as a competitive differentiator for large companies, generative AI for drug development, and what Greg and BMS look for in potential partners. They also highlight the importance of being agile and adaptable while navigating the changing landscape of biotech, providing valuable insights for founders.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.